PEDIATRIX MEDICAL GROUP INC (MD)
US58502B1061 - Common Stock
MD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 113 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of MD have multiple concerns. MD has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
In the past year MD was profitable.
MD had a positive operating cash flow in the past year.
In multiple years MD reported negative net income over the last 5 years.
In the past 5 years MD always reported a positive cash flow from operatings.
1.2 Ratios
MD has a worse Return On Assets (-12.22%) than 70.80% of its industry peers.
MD has a Return On Equity of -34.65%. This is in the lower half of the industry: MD underperforms 65.49% of its industry peers.
The Return On Invested Capital of MD (7.43%) is better than 76.11% of its industry peers.
MD had an Average Return On Invested Capital over the past 3 years of 7.31%. This is in line with the industry average of 8.10%.
The 3 year average ROIC (7.31%) for MD is below the current ROIC(7.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.22% | ||
| ROE | -34.65% | ||
| ROIC | 7.43% |
ROA(3y)1.64%
ROA(5y)-11%
ROE(3y)4.98%
ROE(5y)-38.31%
ROIC(3y)7.31%
ROIC(5y)6.29%
1.3 Margins
MD has a better Operating Margin (8.20%) than 79.65% of its industry peers.
MD's Operating Margin has declined in the last couple of years.
MD does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.2% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3Y-7.23%
OM growth 5Y-11.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, MD has more shares outstanding
The number of shares outstanding for MD has been reduced compared to 5 years ago.
The debt/assets ratio for MD is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.68, we must say that MD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MD (1.68) is comparable to the rest of the industry.
The Debt to FCF ratio of MD is 5.44, which is a neutral value as it means it would take MD, 5.44 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.44, MD is in the better half of the industry, outperforming 77.88% of the companies in the same industry.
MD has a Debt/Equity ratio of 0.83. This is a neutral value indicating MD is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.83, MD is not doing good in the industry: 61.06% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.44 | ||
| Altman-Z | 1.68 |
ROIC/WACC0.97
WACC7.68%
2.3 Liquidity
MD has a Current Ratio of 1.42. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD has a Current ratio (1.42) which is in line with its industry peers.
MD has a Quick Ratio of 1.42. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD has a Quick ratio (1.42) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
The earnings per share for MD have decreased by -7.80% in the last year.
The earnings per share for MD have been decreasing by -19.89% on average. This is quite bad
The Revenue has decreased by -0.25% in the past year.
The Revenue has been growing slightly by 2.97% on average over the past years.
EPS 1Y (TTM)-7.8%
EPS 3Y0%
EPS 5Y-19.89%
EPS Q2Q%37.5%
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y4.78%
Revenue growth 5Y2.97%
Sales Q2Q%0.9%
3.2 Future
Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 0.14% on average per year.
MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.44% yearly.
EPS Next Y10.47%
EPS Next 2Y11.85%
EPS Next 3Y8.86%
EPS Next 5Y0.14%
Revenue Next Year-1.2%
Revenue Next 2Y-1.99%
Revenue Next 3Y-0.66%
Revenue Next 5Y3.44%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 11.15, which indicates a very decent valuation of MD.
Compared to the rest of the industry, the Price/Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 91.15% of the companies listed in the same industry.
MD is valuated cheaply when we compare the Price/Earnings ratio to 28.65, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 9.19 indicates a reasonable valuation of MD.
Based on the Price/Forward Earnings ratio, MD is valued cheaper than 93.81% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of MD to the average of the S&P500 Index (23.56), we can say MD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.15 | ||
| Fwd PE | 9.19 |
4.2 Price Multiples
MD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MD is cheaper than 87.61% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MD indicates a rather cheap valuation: MD is cheaper than 89.38% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.8 | ||
| EV/EBITDA | 7.71 |
4.3 Compensation for Growth
MD's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.06
PEG (5Y)N/A
EPS Next 2Y11.85%
EPS Next 3Y8.86%
5. Dividend
5.1 Amount
MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PEDIATRIX MEDICAL GROUP INC
NYSE:MD (11/20/2024, 8:04:00 PM)
After market: 14.6 +0.11 (+0.76%)14.49
-0.12 (-0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.24B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.15 | ||
| Fwd PE | 9.19 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.06
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.22% | ||
| ROE | -34.65% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 8.2% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.97
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-7.8%
EPS 3Y0%
EPS 5Y
EPS Q2Q%
EPS Next Y10.47%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y4.78%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y